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Background: Elevated numbers of circulating ﬁbrocytes are associatedwith inadequately controlled asthma, poor
response to available therapies, and increased risk of adverse outcomes. The lack of reliable and clinically-
applicable assays precludes a proper evaluation of blood ﬁbrocyte count as a prognostic biomarker in asthma.
This report concerns the use of a multiparameter ﬂow cytometry assay for the enumeration of ﬁbrocytes in the
whole blood.
Methods: Consenting ﬁbrocyte donors were 19 patients with asthma well controlled by current treatment, 16
patients with treatment-resistant asthma, 9 patients with transiently uncontrolled asthma and 14 age-
matched normal individuals. Blood sampling was performed once in patients with transiently uncontrolled
asthma and twice, at an interval of one week, in the other subjects. The assay was performed in 100 μl of
whole blood and involved a sequential gating strategy and absolute ﬁbrocyte counting with a single instrument
(single-platform assay).
Results: The quantiﬁcation of circulating ﬁbrocytes by this assay was analytically and clinically valid. In in-
dividuals with stable clinical conditions, the repeatability of blood ﬁbrocyte counts over one week was
good. The intraclass correlation coefﬁcient was 0.939 and 96.88% of the total variability reﬂected on-
average differences among the tested subjects. Stabilized blood samples could be stored at 4 °C for up to
96 h before processing.
Conclusions: The novel assay for the enumeration of ﬁbrocytes in the whole blood is reliable and clinically
applicable.
General signiﬁcance: This report demonstrates the validity and reliability of the ﬁrst optimized assay for the
enumeration of circulating ﬁbrocytes in multicenter clinical trials.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Asthma is a common inﬂammatory disorder of the airway for which
there is no cure [1]. Optimal asthma management consists in the
achievement and maintenance of the best possible clinical control andAlexa Fluor; α-SMA, α-smooth
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. This is an open access article underin the prevention of disease exacerbations, which are most frequently
triggered by allergen exposure and viral infections and increase the
risk of future adverse outcomes [1,2]. Clinical parameters of asthma con-
trol include the frequency of symptoms during the day and at night or
on awakening, presence of activity limitation because of symptoms,
and level of airﬂow obstruction [1]. The lack of clinical control of asthma
reﬂects ongoing airway inﬂammation and indicates inadequate anti-
inﬂammatory treatment [1,2]. When patients with asthma responsive
to the currently available anti-inﬂammatory therapies suffer from an
acute exacerbation of their disease, asthma control can be achieved
again by increasing the intensity of the anti-inﬂammatory treatment.
In contrast, patients with treatment-resistant disease have frequent
signs and symptoms of airﬂow obstruction, severe exacerbations re-
quiring hospitalization, and persistent airway inﬂammation not
responding to available therapies. Ongoing airway inﬂammation is as-
sociatedwith an increased risk of adverse outcomes because the chronicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tural changes in the bronchial tubes that lead to ﬁxed airway narrowing
and progressive loss of lung function [1,2]. Easily accessible biomarkers
of airway inﬂammation and asthma control are therefore needed for
monitoring the effects of available treatments in patients at increased
risks of adverse outcomes and to assess their responsiveness to novel
therapeutic candidates in clinical trials [2–4]. Blood ﬁbrocyte count is
emerging as one of these easily accessible biomarkers.
The ﬁbrocytes are circulating CD45+CD34+HLA-DR+CD11b+
CD13+CD16−CD115− cells that exhibit both hematopoietic and
stromal-like features and possess antigen-presenting activity [5–9].
They produce several cytokines and growth factors and express type
I collagen (COL1) genes and protein [5,7,10,11]. Their proinﬂamma-
tory and proﬁbrotic properties [6,9–11] are relevant to asthma [9,
12–15], and there is mounting evidence [12–18] that these cells sub-
stantially contribute to the progression of the structural changes
that ultimately lead to ﬁxed airway narrowing in patients with fre-
quent exacerbations and treatment-resistant disease. Elevated
numbers of ﬁbrocytes are present in the circulation and in the air-
ways of these patients [10,14,17,18] as a result of the release of
ligands of the C\C chemokine receptor 5 and other cytokines that
are known to mediate the output of ﬁbrocytes from the bone mar-
row and their recruitment to the inﬂamed tissue [18,19]. Moreover,
the presence of an elevated number of ﬁbrocytes in the peripheral
blood of asthmatic individuals with inadequately controlled disease
not only reﬂects ongoing airway inﬂammation [10,14,18] but is also
associated with persistent airﬂow obstruction and accelerated reduc-
tion of lung function over time [17]. Thus, elevated blood ﬁbrocyte
counts in asthma are indicative of inﬂammatory and structural alter-
ations that can otherwise be detected in a non-invasive way solely by
combining cellular analysis of induced sputum with high-resolution
computed tomography [20]. The use of blood ﬁbrocyte count as an asth-
ma outcomemay also be advantageous in comparison with other prog-
nostic biomarkers because it does not seem to be affected by treatment
with corticosteroids. In fact, patients with treatment-refractory asthma
by deﬁnition use the highest possible dose of inhaled corticosteroids,
often in combination with oral corticosteroids, and yet they have sub-
stantially higher numbers of ﬁbrocytes in their peripheral blood and air-
ways than patients with treatment-responsive asthma of any severity
[14,18].
Unfortunately, the evaluation of the validity and utility of blood
ﬁbrocyte count as a novel cellular biomarker in asthma is currently
precluded by the absence of reliable and clinically-applicable analytical
assays. The experiments described in the present report were therefore
conducted to evaluate the clinical applicability of an optimizedmultipa-
rameter ﬂow cytometry assay for the enumeration of ﬁbrocytes in the
whole blood, which involves a sequential gating strategy and direct
absolute ﬁbrocyte counting with a single instrument by using the
single-platform technology [21–23].
2. Materials and methods
2.1. Patients
The experiments were conducted during the course of two recently
published studies [16,18], according to protocols approved by the
appropriate review board, and the results are cumulatively reported
here. Consenting ﬁbrocyte donors were 19 patients with asthma well
controlled by current treatment [18], 16 patients with treatment-
resistant asthma [18], 9 patients with transiently uncontrolled asth-
ma because of an allergen-induced exacerbation [16], and 14 age-
matched normal individuals [16]. The demographic and clinical
characteristics of these patients are described in every detail in the
two published articles [16,18]. Blood sampling was performed
once in patients with transiently uncontrolled asthma and twice,
at an interval of one week, in the other subjects.2.2. Enumeration of circulating ﬁbrocytes
Blood specimens were collected by venipuncture into evacuated
tubes containing tripotassium ethylenediamine tetraacetate anticoagu-
lant. Aliquots of the blood samples were either left untreated, and proc-
essed within 4 h, or mixed with the cellular surface antigen-stabilizing
agent TransFix (200 μl per 1000 μl blood, Life Technologies, Carlsbad,
CA, USA) [24,25] and stored at 4 °C for up to 96 h before processing.
One hundred μl of treated or untreated blood were added to a 5-ml
round-bottom tube containing 2 μl of the viability dye 7-amino-
actinomycin-D (7-AAD, BD Biosciences, San Jose, CA, USA), which is de-
tected on the PerCP-Cy5.5 channel, and appropriate dilutions in stain
buffer (BD Biosciences) of the following ﬂuorochrome-labeled mono-
clonal antibodies (all mouse IgG1κ): 2.5 μl CD3-PerCP-Cy5.5, 2.5 μl
CD19-PerCP-Cy5.5, 2.5 μl CD20-PerCP-Cy5.5, 2.5 μl CRTH2/CD294-
PerCP-Cy5.5, 5 μl CD45-AmCyan, 5 μl CD34-PE, 5 μl CD11b-Paciﬁc Blue
(PB), 10 μl CD16-FITC (BD Biosciences), and 5 μl CD115-APC (R&D Sys-
tems Europe, Abingdon, United Kingdom). After incubation for 20 min
at room temperature in the dark, erythrocytes were lysed with 2 ml
ﬁxative-free High-Yield Lyse solution (Life Technologies). CountBright
absolute counting beads (Life Technologies) were added to allow an
absolute count of the target cell population according to the
manufacturer's instruction, and samples were analyzed immediately
without any wash steps.
The ﬂow cytometer was a 4-laser BD SLRII (BD Biosciences) and the
instrument was set up using BD Cytometer Setup and Tracking beads.
Data were acquired and analyzed with the BD FACSDiva software (BD
Biosciences). Compensation settings were performedwith a set of com-
pensation tubes using the BD CompBead antibody-capturing particles
and the compensation setup tool in the BD FACSDiva software. Antibod-
ies were titered for no-wash staining. Fluorescence-minus-one controls
were used for accurate deﬁnition of cells that had ﬂuorescence above
the background levels [26].
The gating strategy applied for the enumeration of ﬁbrocytes is
shown in Fig. 1. Because circulating ﬁbrocytes are present in the
CD45+ blood mononuclear cell (BMC) fraction [5–7], this population
was initially gated on the basis of the side scatter (SSC) characteristics
and CD45 expression, and debris and platelets were eliminated. The
beads were gated for counting and excluded from cell analysis. A
dump channel was then established on the PerCP-Cy5.5 channel to ex-
clude 7-ADD+ non-viable cells and some of the unwanted cells that ex-
press CD11b, comprising CD3-positive T lymphocytes, CD19+CD20+ B
lymphocytes and B blasts, CRTH2-positive immature and contaminating
mature eosinophils, and CRTH2+basophils [21,27]. CD45+[7-ADD/CD3/
CD19/CD20/CRTH2]− cells were gated in the plot PerCP-Cy5.5 versus
forward scatter (FSC). Contaminating CD16+CD11b+ neutrophils,
CD115+CD16+CD11b+ monocytes and CD115+ CD16−CD11b+ ma-
ture and immature monocytes [21,28] were than sequentially excluded
from this population by gating CD16- and CD115-negative cells in the
plot CD16-FITC versus SSC and CD15-APC versus SSC, respectively.
Fibrocytes were identiﬁed within the CD45+[7-ADD/CD3/CD19/CD20/
CRTH2]−CD16−CD115− population on the basis of the coexpression
of CD34 and CD11b, which distinguished these cells from the other
remaining CD45+[7-ADD/CD3/CD19/CD20/CRTH2]−CD16−CD115−
cells, including CD45dimCD34+CD11b− blasts/progenitors [29], cir-
culating CD45+CD11b−CD34− myeloid and plasmacytoid dendritic
cells [9,30], and CD45+CD34− CD11b+CD16−CD56+ NK cells [21,
27]. In the CD45/SSC plot, the gated CD45+[CD3/CD19/CD20/
CRTH2]−CD16−CD115−CD11b+CD34+ cells showed an SSC slightly
higher than that of lymphocytes and similar to that of dendritic cells
[27] and somemyeloid progenitors [29]. At least 105 cell events were
acquired for each assay before cell analysis and absolute cell
counting. The intra-assay variability was assessed by analysis of the
absolute ﬁbrocyte counts in three separate 100-μl aliquots of each
blood sample. The coefﬁcient of variation ranged from 2.84 to
5.73% in fresh blood samples, from 4.15 to 8.28% in blood samples
Fig. 1.Gating strategy for the enumeration of viableCD45+[CD3/CD19/CD20/CRTH2]−CD16−CD115−CD11b+CD34+ﬁbrocytes in thewholeblood. Absolute counting beadswere success-
fully resolved from cells and gated for counting. The representative assay was performed with the fresh blood sample of a patient with treatment-resistant asthma. 7-AAD, 7-amino-
actinomycin-D; FSC, forward scatter; PB, Paciﬁc Blue; SSC, side scatter.
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96 h.
2.3. Phenotypic and functional analysis of sorted cells
Blood was collected into BD Vacutainer Glass Mononuclear Cell
Preparation Tubes (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
and BMCswere isolated according to themanufacturer's instruction.
Cells (1 × 107/ml stain buffer) were treated with 5% normal mouse
serum (Sigma-Aldrich, St. Louis, MO, USA) for 10 min prior to stain-
ing with 7-AAD and the antibody cocktail mentioned above. Viable
CD45+[CD3/CD19/CD20/CRTH2]−CD16−CD115−CD11b+CD34+ cells
were aseptically sorted on a 4-laser BD FACS Aria II cytometer (BD Bio-
sciences) using the BD FACSDiva software and the same setting proce-
dures and gating strategy indicated above.
Sorted cells were cultured for 6 days in Dulbecco's modiﬁed Eagle's
medium and nutrient mix Ham's F12 (1:1), containing glutamine
(2 mmol/l), sodium pyruvate (1 mmol/l), nonessential amino acids
(1% vol/vol), penicillin (50 U/ml), streptomycin (50 U/ml,) and 0.5%
fetal calf serum(all from Life Technologies), in the presence or in the ab-
sence of 1 ng/ml endothelin-1 (ET-1, Merck Calbiochem, Darmstadt,
Germany). Medium was replaced on the third day. Analysis of the ex-
pression of COL1 and α-smooth muscle actin (α-SMA) was performed
before and at the end of the incubation period by ﬂow cytometry. For
intracellular staining, cells were ﬁxed and permeabilized with the FIX
& PERM kit (Life Technologies) and incubated with either an unconju-
gated anti-COL1 mouse IgG1 (Merck Millipore, Darmstadt, Germany)
or mouse α-SMA-Alexa Fluor (AF) 700 IgG2A (R&D Systems). COL1 im-
munoreactivity was detected with an APC-conjugated goat anti-mouse
IgG, F(ab′)2 (Santa Cruz Biotechnology, Dallas, TX, USA). Nonspeciﬁc
staining was assessed by using the following recommended isotype
controls for intracellular staining in place of the primary antibodies:
unconjugated mouse IgG1 (BD Biosciences) and AF 700-conjugated
mouse IgG2A (R&D Systems). By using aseptically sorted ﬁbrocytes
from 3 asthmatic patients with relatively high blood ﬁbrocyte counts,
the expression of COL1 was conﬁrmed at the gene level. Gene expres-
sion analysis was performed by reverse-transcription and real time
polymerase chain reaction with the use of a SYBR Green-based cells-
to-threshold cycle (CT) kit (Life Technologies) for small cell samples,
as previously described [10]. Speciﬁc primers for the target geneCOL1A1, encoding the pro-α1 chain of COL1 (http://www.ncbi.nlm.
nih.gov/gene/1277), were those used in a previous study [11]. The
primer pairs for the reference gene ACTB, encoding β-actin (http://
www.ncbi.nlm.nih.gov/gene/60), were included in the control kit from
Life Technologies.
2.4. Statistical analysis
Differences across groups were analyzed by one-way analysis of
variance followed by post-hoc Tukey comparison between groups.
Repeatability of the ﬁbrocyte counts over one week was assessed by
Student's t test for paired data, correlation analysis and calculation of
the intra-class correlation coefﬁcient (ICC) as a reliability index (one-
way random effect model) [31]. Agreement between ﬁbrocyte counts
determined in fresh and stored blood sampleswas assessed by linear re-
gression analysis, Student's t test for paired data and calculation of the
concordance correlation coefﬁcient (CCC) [31]. The Bland–Altman
plots were constructed to display repeatability of ﬁbrocyte counts and
the between-method comparison results [32]. The association between
ﬁbrocyte counts and clinical variables was assessed by calculating the
Pearson correlation coefﬁcient or the Spearman rank correlation coefﬁ-
cient, as appropriate. A p-value of less than 0.05 was considered to be
statistically signiﬁcant. Fibrocyte counts by group were reported as the
means, standard deviations (SDs) and 95% conﬁdence intervals (CIs).
3. Results
3.1. Ability of the single-platform assay to identify authentic ﬁbrocytes
Proof-of-principle experiments were conducted in 3 patients with
asthma well controlled by current treatment and 3 patients with
treatment-resistant diseasewhowere known to have appreciable num-
bers of authenticﬁbrocytes in their peripheral blood, on thebasis of data
collected at an earlier time point of the study and reported elsewhere
[18]. Blood samples were analyzed by using the single-platform assay
for the enumeration of ﬁbrocytes as viable CD45+[CD3/CD19/
CD20/CRTH2]−CD16−CD115−CD11b+CD34+ cells (Fig. 1). To evalu-
ate the nature of the cells identiﬁed by this assay, circulating viable
CD45+[CD3/CD19/CD20/CRTH2]−CD16−CD115−CD11b+CD34+ cells
were sorted from the BMCs and analyzed for the expression of COL1
Fig. 2. Analytical validity of the assay demonstrated by analysis of the expression of type I collagen protein and gene in sorted viable CD45+[CD3/CD19/CD20/CRTH2]−CD16−CD115−
CD11b+CD34+ ﬁbrocytes. (A) Representative ﬂow cytometry analysis of the expression of intracellular type I collagen (COL1). The black line indicates staining with a speciﬁc anti-
COL1 monoclonal antibody and the gray line shows nonspeciﬁc staining with the isotype control (B) Quantitative analysis of the expression of intracellular COL1. The geometric mean
ﬂuorescence intensity (MFI) for COL1 was divided by the corresponding value obtained with the isotype control. The graph shows individual geometric MFI ratio values obtained with
the cells from 3 patients with controlled asthma (squares) and 3 patients with treatment-resistant asthma (circles). The horizontal lines indicate themeans. (C) Analysis of the expression
of the gene encoding the pro-α1 chain of COL1 (COL1A1) by reverse-transcription and real time polymerase chain reaction. The graph shows a representative example of quantiﬁcation by
using the relative standard curve method, where the mean threshold cycle (CT) values from duplicate reactions are plotted against the log of the number of cells used in the reaction. The
endogenous control was ACTB, the gene encodingβ-actin. The normalized levels of expression of COL1A1 in sortedﬁbrocytes from 3 patientswith treatment-resistant asthmawere 0.255,
0.334 and 0.469 (ΔCT method with efﬁciency correction).
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immunoreactivity for COL1 was detected in the sorted cells from
all 6 ﬁbrocyte donors (Fig. 2A and B) and the percentage of COL1+
cells in individual samples ranged from 88.9% to 97.4%. COL1 expres-
sion was also conﬁrmed at the gene level (Fig. 2C). Furthermore,
sorted cells produced higher levels of α-SMA when cultured in theFig. 3. Analytical validity of the assay demonstrated by analysis of the response of sorted viable
with endothelin-1 (ET-1). (A) Representative ﬂow cytometry analysis of the expression of intra
incubated for 6 days in culturemediumalone or in culturemedium supplementedwith1 ng/ml
the gray lines show nonspeciﬁc staining with the isotype control. (B) Quantitative analysis of th
α-SMA was divided by the corresponding value obtained with the isotype control. The graphs
controlled asthma (squares) and 3 patients with treatment-resistant asthma (circles) under eapresence of ET-1 than in culture medium alone, while freshly sorted
and uncultured cells did not express the contractile protein (Fig. 3A
and B). These experiments conﬁrmed that the circulating CD45+[CD3/
CD19/CD20/CRTH2]−CD16−CD115−CD11b+CD34+ cells are authentic
ﬁbrocytes and demonstrated the analytical validity of the single-
platform assay.CD45+[CD3/CD19/CD20/CRTH2]−CD16−CD115−CD11b+CD34+ ﬁbrocytes to stimulation
cellularα-smoothmuscle actin (α-SMA) in freshly sorted and uncultured cells and in cells
ET-1. The black lines indicate stainingwith a speciﬁc antiα-SMAmonoclonal antibody and
e expression of intracellular α-SMA. The geometric mean ﬂuorescence intensity (MFI) for
show individual geometric MFI ratio values obtained with the cells from 3 patients with
ch experimental condition. The horizontal lines indicate the means. AF, Alexa Fluor.
Fig. 5. Repeatability of the ﬁbrocyte counts over one week in healthy subjects (triangles),
patients with controlled asthma (squares) and patients with treatment-resistant asthma
(circles). The Bland–Altman plot displays the differences in ﬁbrocyte counts between
day 1 and day 2 as a percentage of the average counts versus the average values, with in-
dividual % differences, themean value and the limits of agreement. ICC, intraclass correla-
tion coefﬁcient; SD, standard deviation; SS, sum of squares (from analysis of variance, one
way randommodel).
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To investigate the ability of the single-platform assay to provide
measures that correlatewith the level of asthma control and therapeutic
responsiveness, the blood ﬁbrocyte counts obtained in patients with
controlled asthma and patients with treatment-resistant disease by
this method were compared with the counts similarly measured in
patients with asthma transiently uncontrolled by current treatment, be-
cause of an exacerbation triggered by allergen exposure, and in healthy
controls. Patients with transiently uncontrolled asthma and those with
treatment-resistant disease had signiﬁcantly elevated numbers of circu-
lating ﬁbrocytes in comparison with the other groups, while there were
no statistically signiﬁcant differences between the ﬁbrocyte counts ob-
tained in patients with controlled asthma and healthy individuals
(Fig. 4). Although all patients with transiently uncontrolled asthma
were suffering from a disease exacerbation triggered by allergen expo-
sure, the atopic status alone did not appear to have an inﬂuence on
the number of circulating ﬁbrocytes because atopic subjects were pres-
ent in all groups (Fig. 4). In asthmatic subjects, the blood ﬁbrocyte
counts did not correlate with the duration of asthma or measures of
lung function alone (all p N 0.05).
3.3. Repeatability of ﬁbrocyte counts by the single-platform assay
The enumeration of ﬁbrocytes was performed again in consenting
subjects at an interval of one week from the ﬁrst blood sampling.
Among the asthmatic patients, those with well-controlled asthma and
treatment-resistant disease could be retested because they did not
show notable changes in their clinical and functional characteristics.
Comparative analysis of the blood ﬁbrocyte counts obtained on the
two occasions revealed low variability of the measures over one week
(Fig. 5). The ICC represents the ratio of inter-subject variability to total
variability and its high value denotes a good reproducibility of theFig. 4. Comparison of ﬁbrocyte counts in the whole blood of healthy individuals and asth-
matic patients. The graph shows individual values and the median value (horizontal line)
for each group. Closed symbols represent atopic individuals. The dotted line indicates the
upper limit of the 95% conﬁdence interval (CI) in healthy subjects. The mean numbers of
ﬁbrocytes/μl blood, standard deviations and 95% CIs were 9.41, 5.92, 5.99–12.8 in healthy
subjects; 14.05, 8.28, 10.06–18.04 in patients with controlled asthma; 30.42, 8.84, 23.62–
37.21 in patients with transiently uncontrolled asthma; and 22.46, 9.65, 17.31–27.60 in
patients with treatment-resistant asthma.measures. The variation attributable to the procedure was very low
(1− η2 = 0.031), with 96.88% of the total variability reﬂecting on-
average differences among the 49 subjects.
3.4. Comparison of ﬁbrocyte counts in fresh and stored blood samples
At the time of the second blood sampling in asthmatic patients and
healthy controls, an aliquot of each blood sample was treated with the
antigen-stabilizing agent and stored for 48 or 96 h at 4 °C before
ﬁbrocyte enumeration by using the single-platform assay. Robust
between-method comparison bymultiple statistical tests demonstrated
a good agreement between the ﬁbrocyte counts measured in fresh
whole blood and the ﬁbrocyte counts obtained in stored whole blood
at 48 and 96 h (Fig. 6A–D).
4. Discussion
The methods currently used to identify authentic ﬁbrocytes in the
peripheral blood and to purify them for functional analyses [9,10,14,
16–18] are costly and time-consuming. Moreover, most of these
methods involve the isolation of BMCs, which requires a large volume
of venous blood because of the considerable cellular loss. The enumera-
tion of CD34+COL1mRNA+ ﬁbrocytes on cytospins of blood leukocytes
from normal and asthmatic subjects was previously performed to deﬁ-
nitely ascertain if authentic ﬁbrocytes are really present in the peripher-
al blood [10]. Because of the relatively low numbers of circulating
ﬁbrocytes, this method cannot be used on a large scale. Initial attempts
to quantify ﬁbrocytes in the leukocyte-enriched fraction of the whole
blood by staining for intracellular COL1 have raised technical concerns
[34]. More recently reported methods involve COL1 staining without
previous cell permeabilization [35]. Thus, there is a lack of analytically
valid and standardized assays for the enumeration of blood ﬁbrocytes
in a clinical setting and inmulticenter clinical trials. Moreover, all previ-
ously describedﬂow cytometry assays for the enumeration of ﬁbrocytes
in BMCs or in the leukocyte-enriched fraction of the whole blood
Fig. 6. Comparison of ﬁbrocyte counts determined in fresh blood samples and in stabilized samples stored for 48 (A and B) or 96 (C andD)hours before processing. Panels A and C show the
results of the linear regression analysis and the dotted line is the line of identity. Panels B and D show the Bland–Altman analysis by groups: healthy subjects (triangles), patients with
controlled asthma (squares) and patients with treatment-resistant asthma (circles). The Bland–Altman plot displays the differences between the ﬁbrocyte counts in fresh samples and
those in stored samples as a percentage of the average counts versus the average values, with individual % differences, themean value and the limits of agreement. CCC, concordance cor-
relation coefﬁcient; CI, conﬁdence interval; SD, standard deviation.
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precise absolute cell counts [22].
The assay presented here is based on the single-platform counting
technology, which is superior to the dual-platform approach in clinical
trials because it greatly reduces the sources of variability, minimizes
the risks of inaccuracy and improves inter-laboratory comparisons
[22], particularly when the target cells represent a small percentage of
the circulating leukocytes [36]. The assay eliminates three additional
sources of variability speciﬁcally associated with the identiﬁcation of
circulating ﬁbrocytes on the basis of the expression of intracellular
COL1 by ﬂow cytometry. Firstly, intracellular staining requires cells ﬁx-
ation and permeabilization and these procedures alter the light-scatter
characteristics of the cells, increases autoﬂuorescence and reduces
the reactivity of the other ﬂuorochrome-labeled antibodies included
in the assay [37]. Secondly, cytoplasmic antigens require careful an-
tibody titration because antibody binding is not saturable, and non-
speciﬁc binding increases with each increase in antibody concentra-
tion [37,38]. Thirdly, the percentage of circulating CD34+COL1
mRNA+ ﬁbrocytes that express COL1 immunoreactivity is higher in
asthmatic than in normal ﬁbrocytes and may change over time
[10]. Lastly, the frequency of circulating cells expressing receptors
with a collagenous domain increases in some ﬁbrotic conditions
and in patients treated with systemic corticosteroids and such cells
nonspeciﬁcally stain for COL1 [9]. Cell ﬁxation and permeabilization
also involve several washing steps that lead to an inevitable cell losswhen decanting. Thus, staining for intracellular COL1 precludes a
correct application of the single-platform counting method, which
is only possible if any cell loss can be avoided before analysis with
the use of the lyse-no-wash approach [22].
In the assay described here, the risk of non-speciﬁc staining aremin-
imized as much as possible by adopting the following technical strate-
gies [26,29,37]: non-viable cells are excluded; the effects of Fcγ
receptor-mediated binding of antibodies are eliminated by excluding
granulocytes and monocytes; ﬁbrocytes are identiﬁed by sequential
gating with the use of multiple surface markers; ﬂuorescence-minus-
one controls are employed for accurate deﬁnition of cells that haveﬂuo-
rescence above the background levels. Because of this strategic ap-
proach, isotype controls are not needed. Notably, identical results are
obtained in fresh blood assays where the anti-CD16 antibody is omitted
because CD16+ nonocytes are however excluded by gating out CD115+
cells and CD16+ neutrophils can be easily recognized on the basis of
their high SSC. Nonetheless, the use of this antibody is important for ex-
cluding contaminating neutrophils in stabilized and storedwhole blood,
where slight changes in the SSC of granulocytes are commonly observed
[25].
The enumeration of circulating ﬁbrocytes by using the single-
platform technology requires only 100 μl of venous blood. The assay is
analytically valid because the enumerated cells are authentic ﬁbrocytes,
on the basis of their phenotype (CD45+CD34+CD11b+COL1+ cells) and
functional characteristics (α-SMA expression in response to stimulation
58 L. Bianchetti et al. / BBA Clinical 1 (2014) 52–58with ET-1). The assay is clinically valid because it is able to distinguish
subjects with symptomatic asthma from healthy individuals and to
detect signiﬁcant differences among asthmatic patients on the basis of
the level of asthma control and response to treatment.Moreover, the re-
producibility of blood ﬁbrocyte counts over one week is high in healthy
individuals and asthmatic subjects with stable clinical conditions. The
observation that stabilized blood samples can be stored at 4 °C for up
to 96 h before analysis by using the single-platform assay is particularly
important for the application of the assay in multicenter clinical trials,
which require all analyses to be performed at a central laboratory.
In conclusion, this report describes the development and validation
of a novel single-platform ﬂow cytometry assay for the enumeration
of circulating ﬁbrocytes in the clinical setting and inmulticenter clinical
trials. The assay can be used to evaluate the utility and validity of blood
ﬁbrocyte count as an outcome measure in asthma. The description of a
reliable and clinically applicable assay for the enumeration of ﬁbrocytes
in the whole blood is also of paramount importance for the conduction
of translational research and clinical studies in other inﬂammatory
and immunological disorders associated with tissue ﬁbrosis, where
ﬁbrocytes may play a signiﬁcant pathogenetic role [39].
Disclosures
S. Mattoli is founding shareholder and director of AVAIL GmbH. Her
husband is a senior pharmaceutical executive and holds the shares of
diverse pharmaceutical corporations and biotechnology industries.
The other authors have no conﬂicts of interest or ﬁnancial interests to
disclose.
Author contributions
All authors made substantial contributions to study conception and
design, or data acquisition, or data analysis and interpretation; drafting
or critically revising the manuscript; ﬁnal approval of the submitted
version.
Funding sources
Funding sourceswere fromDreiRosen Pharma (Research Fellowship
to L.B.) and the international research projects FibroGENE (IRP 261009)
and CellNet (IRP 210610).
References
[1] Global Initiative for Asthma (GINA), Global strategy for asthma management and
prevention, Updated 2012, Available at: http://www.ginasthma.com (last accessed
on 06 March 2013).
[2] H.K. Reddel, D.R. Taylor, E.D. Bateman, et al., An ofﬁcial American Thoracic Society/
European Respiratory Society statement: asthma control and exacerbations. Stan-
dardizing endpoints for clinical asthma trials and clinical practice, Am. J. Respir.
Crit. Care Med. 180 (2009) 59–99.
[3] C.E. Jia, H.P. Zhang, Y. Lv, et al., The Asthma Control Test and Asthma Control
Questionnaire for assessing asthma control: systematic review and meta-analysis,
J. Allergy Clin. Immunol. 131 (2013) 695–703.
[4] A.T. Hastie, W.C. Moore, H. Li, et al., Biomarker surrogates do not accurately predict
sputum eosinophil and neutrophil percentages in asthmatic subjects, J. Allergy Clin.
Immunol. 132 (2013) 72–80.
[5] R. Bucala, L.A. Spiegel, J. Chesney, M. Hogan, A. Cerami, Circulating ﬁbrocytes deﬁne
a new leukocyte subpopulation that mediates tissue repair, Mol. Med. 1 (1994)
71–81.
[6] J. Chesney, C. Metz, A.B. Stavitsky, M. Bacher, R. Bucala, Regulated production of type
I collagen and inﬂammatory cytokines by peripheral blood ﬁbrocytes, J. Immunol.
160 (1998) 419–425.
[7] R. Abe, S.C. Donnelly, T. Peng, R. Bucala, C.N. Metz, Peripheral blood ﬁbrocytes:
differentiation pathway and migration to wound sites, J. Immunol. 166 (2001)
7556–7562.
[8] J. Chesney, M. Bacher, A. Bender, R. Bucala, The peripheral blood ﬁbrocyte is a potent
antigen-presenting cell capable of priming naive T cells in situ, Proc. Natl. Acad. Sci.
U. S. A. 94 (1997) 6307–6312.
[9] M. Isgrò, L. Bianchetti, M.A. Marini, S. Mattoli, Involvement of ﬁbrocytes in allergen-
induced T cell responses and rhinovirus infections in asthma, Biochem. Biophys. Res.
Commun. 437 (2013) 446–451.[10] A. Bellini, M.A. Marini, L. Bianchetti, M. Barczyk, M. Schmidt, S. Mattoli, Interleukin
(IL)-4, IL-13, and IL-17A differentially affect the proﬁbrotic and proinﬂammatory
functions of ﬁbrocytes from asthmatic patients, Mucosal Immunol. 5 (2012)
140–149.
[11] L. Bianchetti, M. Barczyk, J. Cardoso, M. Schmidt, A. Bellini, S. Mattoli, Extracellular
matrix remodelling properties of human ﬁbrocytes, J. Cell. Mol. Med. 16 (2012)
483–495.
[12] M. Schmidt, G. Sun, M.A. Stacey, L. Mori, S. Mattoli, Identiﬁcation of circulating
ﬁbrocytes as precursors of bronchial myoﬁbroblasts in asthma, J. Immunol. 170
(2003) 380–389.
[13] K. Nihlberg, K. Larsen, A. Hultgårdh-Nilsson, A. Malmström, L. Bjermer, G.
Westergren-Thorsson, Tissue ﬁbrocytes in patients with mild asthma: a possible
link to thickness of reticular basement membrane? Respir. Res. 7 (2006) 50.
[14] R. Saunders, S. Siddiqui, D. Kaur, et al., Fibrocyte localization to the airway smooth
muscle is a feature of asthma, J. Allergy Clin. Immunol. 123 (2009) 376–384.
[15] A. Bellini, M. Schmidt, S. Mattoli, Interactions between the bronchial epithelium and
ﬁbrocytes in the pathogenesis of airway remodeling in asthma, J. Epithelial Biol.
Pharmacol. 6 (2013) 1–10. http://dx.doi.org/10.2174/1875044301306010001.
[16] L. Bianchetti, M.A. Marini, M. Isgrò, A. Bellini, M. Schmidt, S. Mattoli, IL-33
promotes the migration and proliferation of circulating ﬁbrocytes from
patients with allergen-exacerbated asthma, Biochem. Biophys. Res. Commun.
426 (2012) 116–121.
[17] C.H. Wang, C.D. Huang, H.C. Lin, et al., Increased circulating ﬁbrocytes in asthma
with chronic airﬂow obstruction, Am. J. Respir. Crit. Care Med. 178 (2008)
583–591.
[18] M. Isgrò, L. Bianchetti, M.A. Marini, A. Bellini, M. Schmidt, S. Mattoli, The C\C
motif chemokine ligands CCL5, CCL11, and CCL24 induce the migration of circu-
lating ﬁbrocytes from patients with severe asthma, Mucosal Immunol. 6 (2013)
718–727.
[19] Y. Ishida, A. Kimura, T. Kondo, et al., Essential roles of the CC chemokine ligand
3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary ﬁbrosis
through regulation of macrophages and ﬁbrocyte inﬁltration, Am. J. Pathol.
170 (2007) 843–854.
[20] S.J. Szeﬂer, S. Wenzel, R. Brown, et al., Asthma outcomes: biomarkers, J. Allergy Clin.
Immunol. 129 (2012) S9–S23.
[21] J.L. Faucher, C. Lacronique-Gazaille, E. Frébet, et al., 6 markers/5 colors extended
white blood cell differential by ﬂow cytometry, Cytometry A71 (2007) 934–944.
[22] B. Brando, D. Barnett, G. Janossy, et al., Cytoﬂuorometric methods for assessing abso-
lute numbers of cell subsets in blood. EuropeanWorking Group on clinical cell anal-
ysis, Cytometry 42 (2000) 327–346.
[23] F.F. Mandy, J.K. Nicholson, J.S. McDougal, CDC, Guidelines for performing single-
platform absolute CD4+ T-cell determinations with CD45 gating for persons infect-
edwith human immunodeﬁciency virus. Centers for disease control and prevention,
MMWR Recomm. Rep. 52 (RR-2) (2003) 1–13.
[24] M. Bergeron, A. Shafaie, T. Ding, et al., Evaluation of stabilized blood cell prod-
ucts as candidate preparation for quality assessment programs for CD4 T-cell
counting, Cytometry 50 (2002) 86–91.
[25] B. Canonico, M. Betti, F. Luchetti, et al., Flow cytometry proﬁles, biomolecular and
morphological aspects of transﬁxed leukocytes and red cells, Cytometry B Clin.
Cytom. 78 (2010) 267–278.
[26] S.P. Perfetto, P.K. Chattopadhyay, M. Roederer, Seventeen-colour ﬂow cytometry:
unravelling the immune system, Nat. Rev. Immunol. 4 (2004) 648–655.
[27] P. Autissier, C. Soulas, T.H. Burdo, K.C. Williams, Evaluation of a 12-color ﬂow cy-
tometry panel to study lymphocyte, monocyte and dendritic cell subsets in
humans, Cytometry 77A (2010) 410–419.
[28] M.A. Ingersoll, R. Spanbroek, C. Lottaz, et al., Comparison of gene expression proﬁle
between human and mouse monocyte subsets, Blood 115 (2010) e10–e19.
[29] J.G. Bender, K.L. Unverzagt, D.E. Walker, et al., Identiﬁcation and comparison of
CD34-positive cells and their subpopulations from normal peripheral blood and
bone marrow using multicolour ﬂow cytometry, Blood 77 (1991) 2591–2596.
[30] A. Dzionek, A. Fuchs, P. Schmidt, et al., BDCA-2, BDCA-3, and BDC-4: three markers
for distinct subsets of dendritic cells in human peripheral blood, J. Immunol. 165
(2000) 6037–6046.
[31] M.M. Shoukri, Measures of Interobserver Agreement and Reliability, Second ed.
Chapman & Hall/CRC Press, Boca Raton, FL, 2011.
[32] J.M. Bland, D.G. Altman, Measuring agreement in method comparison studies, Stat.
Methods Med. Res. 8 (1999) 135–160.
[33] C.M. Weng, B.C. Chen, C.H. Wang, et al., The endothelin A receptor mediates
ﬁbrocyte differentiation in chronic obstructive asthma. The involvement of connec-
tive tissue growth factor, Am. J. Respir. Crit. Care Med. 188 (2013) 298–308.
[34] S. Bournazos, A. Fahim, S.P. Hart, Identiﬁcation of ﬁbrocytes in peripheral blood, Am.
J. Respir. Crit. Care Med. 180 (2009) 1279.
[35] L. Fang, X.L. Moore, W. Chan, D.A. White, J. Chin-Dusting, A.M. Dart, Decreased
ﬁbrocyte number is associated with atherosclerotic plaque instability in man,
Cardiovasc. Res. 95 (2012) 124–133.
[36] W.H.B.M. Levering, F.W.M.B. Preijers, W.N. van Wieringen, et al., Flow cytometric
CD34+ stem cell enumeration: lesson from nine years' external quality assessment
within the Benelux countries, Cytometry 72B (2007) 178–188.
[37] B. Wood, 9-Color and 10-color ﬂow cytometry in the clinical laboratory, Arch.
Pathol. Lab. Med. 130 (2006) 680–690.
[38] A.H. Lazarus, J. Ellis, V. Blanchette, J. Freedman, X. Sheng-Tanner, Permeabilization
and ﬁxation conditions for intracellular ﬂow cytometry detection of the T-cell
receptor ζ chain and other intracellular proteins in lymphocyte subpopulations,
Cytometry 32 (1998) 206–213.
[39] C.L. Galligan, E.N. Fish, The role of circulating ﬁbrocytes in inﬂammation and autoim-
munity, J. Leukoc. Biol. 93 (2013) 45–50.
